This study used an observational, retrospective cohort design to compare the presence and
timing of new-onset diabetes (NOD) between hypertensive patients initiating therapy with
carvedilol immediate-release (IR) and carvedilol controlled-release (CR) vs the following
cardioselective beta blockers (BBs): atenolol, metoprolol succinate, and metoprolol tartrate
(referred to hereafter as 'other BB').
The aim of the study was to investigate the likelihood of developing NOD among hypertensive
patients initiating carvedilol therapy vs other BB therapy in a real world setting derived
from data contained in a large United States (US) managed care database.